There is vast scientific knowledge happening beyond our walls and collaboration is a key driver of innovation at Pfizer. We collaborate to accelerate the pace at which good scientific ideas can become promising therapies, building on or complementing our own in-house knowledge. There is a rich and highly networked health ecosystem where multiple organizations are focused on one goal: discover new therapies for patients, as fast as we can.
We work to advance unique models of collaboration with creativity, flexibility and openness to deliver innovation quickly regardless of where the talent and resources live. This includes working with foundations, patients, government, payers, healthcare professionals, academia, consortiums, and competitors in the biopharma industry.
Strategic and Flexible Use of Funding Vehicles
Learn More about Pfizer Collaboration
Biotech and Pharma
Whether we are looking to access early, mid or late stage medicines under investigation, or looking to explore a breaking technology platform that has the potential to be applied to multiple investigational candidates, we pride ourselves in sharing both the risks and rewards of our collaborations.
The key for Pfizer is that we recognize that all potential partners are unique in their own way, and therefore no partnerships are exactly the same. We therefore are flexible in how we partner with different companies; we use a range of investment vehicles and collaboration models in R&D to help ensure we tap into the vast, rapidly-evolving ecosystem of healthcare innovation, looking to complement each other’s capabilities so that together we can make a bigger impact.
These partnerships can have an amplifying and accelerating effect – optimizing the assets and capabilities of the industry partner and making it possible to pursue more research avenues, or de-risk the earlier stage research that is foundational for true medical breakthroughs.
Please see some examples of recent partnerships here:
Centers for Therapeutic Innovation
Pfizer’s Centers for Therapeutic Innovation (CTI) is a pioneering model for collaboration, designed to bridge the gap between early scientific discovery and its translation into new medicines. CTI brings together Pfizer scientists side-by-side with scientists from leading academic medical centers, foundations and government organizations, bringing together some of the best minds to share insights and drive discoveries. CTI represents a unique avenue to tap into leading science outside of Pfizer and engage collaborators early in the drug discovery process. By design, our collaborations are meant to empower and reward our partners with each project’s success.
With locations in Boston, New York, San Diego, and San Francisco, CTI's open innovation model puts Pfizer scientists in the lab with academic investigators, where they share their understanding of target biology and translational medicine expertise. Pfizer provides access to select Pfizer compound libraries, proprietary screening methods, antibody development technologies, and a wealth of dedicated resources and support from Pfizer experts in drug development and protein sciences. The ultimate goal of each collaborative project is to validate a drug candidate that can be moved into further clinical testing.
CTI currently has 34 projects ongoing in the areas of inflammation and immunology, cancer, rare diseases, neuroscience and vaccine research.
In collaborating with academic medical centers, universities and research institutions we hope to help accelerate how their breakthrough research becomes medicines that could treat or cure patients. Pfizer is looking to access novel scientific discoveries earlier in the process, in the hopes of sharing our drug development expertise and turn these into medicines.
In lock-step coordination at every step of the process, we provide our academic collaborators with Pfizer’s expertise in clinical research, drug development, and manufacturing capabilities.
There is promising early scientific discovery happening in government institutions and a great deal of public sector investment supports basic research. In partnering with government-sponsored groups, Pfizer hopes to ensure that public investment into basic research makes its way to patients, faster. Similar to other types of collaborations, if each sector focuses on its core strengths, the health ecosystem and society will benefit from new and better potential medicines.